Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Elite PharmaceuticalsELTP +1.66%60 Debt-to-EBITDA is 0.07 as of Mar. 2026, which is 82% below its 10-year median of 0.38. GuruFocus rates ELTP with a GF Score™ of 60/100 and a GF Value™ of $0.57 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 691 Drug Manufacturers companies, Elite Pharmaceuticals ranks better than 86.11% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Elite Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:
ELTP'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -10.83 Med: 0.38 Max: 4.57
Current: 0.1
During the past 13 years, the highest Debt-to-EBITDA Ratio of Elite Pharmaceuticals was 4.57. The lowest was -10.83. And the median was 0.38.
ELTP's Debt-to-EBITDA is ranked better than 86.11% of 691
companies
in the Drug Manufacturers industry
Industry Median: 1.68
vs ELTP: 0.10
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Elite Pharmaceuticals Debt-to-EBITDA Related Terms
Elite Pharmaceuticals Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Elite Pharmaceuticals's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ELTP vs EOLS, EBS, AQST: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Elite Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elite Pharmaceuticals Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Elite Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Elite Pharmaceuticals's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Elite Pharmaceuticals (ELTP) has a Debt-to-EBITDA of 0.07 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Elite Pharmaceuticals. This is 82% below median its historical median of 0.38. According to the industry distribution chart, Elite Pharmaceuticals ranks #96 out of 691 companies in the Drug Manufacturers industry, placing it in the top 13.9%.
Is Elite Pharmaceuticals' Debt-to-EBITDA too high?
Elite Pharmaceuticals' current Debt-to-EBITDA of 0.07 is 82% below median its 10-year median of 0.38. The Drug Manufacturers industry median Debt-to-EBITDA is 1.68. Elite Pharmaceuticals' value of 0.07 is 95.8% below this industry median. Based on the distribution chart, Elite Pharmaceuticals ranks #96 out of 691 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Elite Pharmaceuticals has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Elite Pharmaceuticals' Debt-to-EBITDA compare to EOLS and EBS?
According to the Drug Manufacturers industry distribution chart, Elite Pharmaceuticals ranks #96 out of 691 companies for Debt-to-EBITDA. This places Elite Pharmaceuticals in the top 14% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.68. Elite Pharmaceuticals' value of 0.07 is 95.8% below this benchmark. While the company's 10-year median is 0.38 vs. the industry median of 1.68, Elite Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.68, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Elite Pharmaceuticals's current Debt-to-EBITDA of 0.07 is 95.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Elite Pharmaceuticals. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elite Pharmaceuticals's current Debt-to-EBITDA is 0.07, which is 82% below median its own 10-year median of 0.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elite Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Elite Pharmaceuticals (ELTP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.57, compared to a current price of $0.38 — trading 33.5% below its estimated fair value. The current Debt-to-EBITDA is 0.07, which is 82% below median its 10-year median of 0.38 and 95.8% below the Drug Manufacturers industry median of 1.68. Elite Pharmaceuticals' overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Elite Pharmaceuticals (ELTP), the current Debt-to-EBITDA is 0.07 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Elite Pharmaceuticals (ELTP) Overvalued in 2026?
Based on GuruFocus' analysis, Elite Pharmaceuticals stock appears to be undervalued.
The current stock price of $0.38 is trading 33.5% below its estimated GF Value™ of $0.57.
GuruFocus considers Elite Pharmaceuticals to be Possible Value Trap.
Key valuation signals for ELTP:
Debt-to-EBITDA: 0.07 (82% below median its 10-year median of 0.38)
GF Value™: $0.57 vs. price of $0.38 (33.5% below fair value)
Industry Position: 95.8% below the Drug Manufacturers median (#96 of 691)
No single metric tells the full story. See the ELTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.
60GF Score
Get the complete analysis for ELTP
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELTP has been successfully added to your 
